Hormonal contraception use and pregnancy in adolescents with sickle cell disease

Analysis of Michigan Medicaid claims

Sarah H. O'Brien, Jennifer Klima, Suzanne Reed, Deena Chisolm, Eleanor Schwarz, Kelly J. Kelleher

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Access to effective family planning is of great importance for women with sickle cell disease (SCD) due to the increased frequency of pregnancy complications. However, little is known regarding use of hormonal contraception, complications of contraception, and pregnancy in young women with SCD. Study Design: We abstracted diagnostic codes, procedure codes and pharmacy claims from women with SCD, aged 13-21 years, enrolled in Michigan Medicaid between 1/1/2000 and 12/31/2003 with ≤ 9 months of continuous eligibility. Results: We identified 250 women with SCD with an average period of continuous Medicaid enrollment of 20 months. Claims for hormonal contraception could be identified in only 20 patients (8%, 95% CI 5-12%). The most commonly prescribed method (n=12) was depot medroxyprogesterone (DMPA) acetate. Venous thromboembolism and osteopenia were rarely identified (n≤10) and occurred only in women with no recorded use of hormonal contraception. In the total population, 64 patients had one pregnancy and 16 had ≤2 pregnancies during the 4-year study period. Among adolescents (13-18 years), 49 (30%) of 195 patients (95% CI 24-37%) had 59 pregnancies. By 12 weeks postpartum, few patients (n≤10) with a record of delivery had hormonal contraception claims. Conclusions: In a publicly insured population of young women with SCD, pregnancy was more commonly identified than hormonal contraception use. Our work suggests that significant gaps may exist in family planning care for young women with SCD.

Original languageEnglish (US)
Pages (from-to)134-137
Number of pages4
JournalContraception
Volume83
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Pregnancy in Adolescence
Medicaid
Sickle Cell Anemia
Contraception
Pregnancy
Pregnancy Complications
Family Planning Services
Medroxyprogesterone Acetate
Metabolic Bone Diseases
Venous Thromboembolism
Postpartum Period
Population

Keywords

  • Adolescents
  • Contraception
  • Pregnancy
  • Sickle cell disease

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Hormonal contraception use and pregnancy in adolescents with sickle cell disease : Analysis of Michigan Medicaid claims. / O'Brien, Sarah H.; Klima, Jennifer; Reed, Suzanne; Chisolm, Deena; Schwarz, Eleanor; Kelleher, Kelly J.

In: Contraception, Vol. 83, No. 2, 01.02.2011, p. 134-137.

Research output: Contribution to journalArticle

O'Brien, Sarah H. ; Klima, Jennifer ; Reed, Suzanne ; Chisolm, Deena ; Schwarz, Eleanor ; Kelleher, Kelly J. / Hormonal contraception use and pregnancy in adolescents with sickle cell disease : Analysis of Michigan Medicaid claims. In: Contraception. 2011 ; Vol. 83, No. 2. pp. 134-137.
@article{9b1e03f5fb064467b18c48c896b7b703,
title = "Hormonal contraception use and pregnancy in adolescents with sickle cell disease: Analysis of Michigan Medicaid claims",
abstract = "Background: Access to effective family planning is of great importance for women with sickle cell disease (SCD) due to the increased frequency of pregnancy complications. However, little is known regarding use of hormonal contraception, complications of contraception, and pregnancy in young women with SCD. Study Design: We abstracted diagnostic codes, procedure codes and pharmacy claims from women with SCD, aged 13-21 years, enrolled in Michigan Medicaid between 1/1/2000 and 12/31/2003 with ≤ 9 months of continuous eligibility. Results: We identified 250 women with SCD with an average period of continuous Medicaid enrollment of 20 months. Claims for hormonal contraception could be identified in only 20 patients (8{\%}, 95{\%} CI 5-12{\%}). The most commonly prescribed method (n=12) was depot medroxyprogesterone (DMPA) acetate. Venous thromboembolism and osteopenia were rarely identified (n≤10) and occurred only in women with no recorded use of hormonal contraception. In the total population, 64 patients had one pregnancy and 16 had ≤2 pregnancies during the 4-year study period. Among adolescents (13-18 years), 49 (30{\%}) of 195 patients (95{\%} CI 24-37{\%}) had 59 pregnancies. By 12 weeks postpartum, few patients (n≤10) with a record of delivery had hormonal contraception claims. Conclusions: In a publicly insured population of young women with SCD, pregnancy was more commonly identified than hormonal contraception use. Our work suggests that significant gaps may exist in family planning care for young women with SCD.",
keywords = "Adolescents, Contraception, Pregnancy, Sickle cell disease",
author = "O'Brien, {Sarah H.} and Jennifer Klima and Suzanne Reed and Deena Chisolm and Eleanor Schwarz and Kelleher, {Kelly J.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.contraception.2010.06.017",
language = "English (US)",
volume = "83",
pages = "134--137",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Hormonal contraception use and pregnancy in adolescents with sickle cell disease

T2 - Analysis of Michigan Medicaid claims

AU - O'Brien, Sarah H.

AU - Klima, Jennifer

AU - Reed, Suzanne

AU - Chisolm, Deena

AU - Schwarz, Eleanor

AU - Kelleher, Kelly J.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: Access to effective family planning is of great importance for women with sickle cell disease (SCD) due to the increased frequency of pregnancy complications. However, little is known regarding use of hormonal contraception, complications of contraception, and pregnancy in young women with SCD. Study Design: We abstracted diagnostic codes, procedure codes and pharmacy claims from women with SCD, aged 13-21 years, enrolled in Michigan Medicaid between 1/1/2000 and 12/31/2003 with ≤ 9 months of continuous eligibility. Results: We identified 250 women with SCD with an average period of continuous Medicaid enrollment of 20 months. Claims for hormonal contraception could be identified in only 20 patients (8%, 95% CI 5-12%). The most commonly prescribed method (n=12) was depot medroxyprogesterone (DMPA) acetate. Venous thromboembolism and osteopenia were rarely identified (n≤10) and occurred only in women with no recorded use of hormonal contraception. In the total population, 64 patients had one pregnancy and 16 had ≤2 pregnancies during the 4-year study period. Among adolescents (13-18 years), 49 (30%) of 195 patients (95% CI 24-37%) had 59 pregnancies. By 12 weeks postpartum, few patients (n≤10) with a record of delivery had hormonal contraception claims. Conclusions: In a publicly insured population of young women with SCD, pregnancy was more commonly identified than hormonal contraception use. Our work suggests that significant gaps may exist in family planning care for young women with SCD.

AB - Background: Access to effective family planning is of great importance for women with sickle cell disease (SCD) due to the increased frequency of pregnancy complications. However, little is known regarding use of hormonal contraception, complications of contraception, and pregnancy in young women with SCD. Study Design: We abstracted diagnostic codes, procedure codes and pharmacy claims from women with SCD, aged 13-21 years, enrolled in Michigan Medicaid between 1/1/2000 and 12/31/2003 with ≤ 9 months of continuous eligibility. Results: We identified 250 women with SCD with an average period of continuous Medicaid enrollment of 20 months. Claims for hormonal contraception could be identified in only 20 patients (8%, 95% CI 5-12%). The most commonly prescribed method (n=12) was depot medroxyprogesterone (DMPA) acetate. Venous thromboembolism and osteopenia were rarely identified (n≤10) and occurred only in women with no recorded use of hormonal contraception. In the total population, 64 patients had one pregnancy and 16 had ≤2 pregnancies during the 4-year study period. Among adolescents (13-18 years), 49 (30%) of 195 patients (95% CI 24-37%) had 59 pregnancies. By 12 weeks postpartum, few patients (n≤10) with a record of delivery had hormonal contraception claims. Conclusions: In a publicly insured population of young women with SCD, pregnancy was more commonly identified than hormonal contraception use. Our work suggests that significant gaps may exist in family planning care for young women with SCD.

KW - Adolescents

KW - Contraception

KW - Pregnancy

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=78651424461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651424461&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2010.06.017

DO - 10.1016/j.contraception.2010.06.017

M3 - Article

VL - 83

SP - 134

EP - 137

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 2

ER -